SION (Sionna Therapeutics) PB Ratio: 6.88 (As of Jul. 04, 2026)


SION Sionna Therapeutics Inc SION
12 GF Score
Price $43.99
! 3 Warning Signs
View Full Analysis

What is Sionna Therapeutics PB Ratio?

Sionna Therapeutics SION +5.64% 12 PB Ratio is 6.88 as of Jul. 04, 2026. GuruFocus rates SION with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 1,228 Biotechnology companies, Sionna Therapeutics ranks worse than 78.01% on this metric.

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-04), Sionna Therapeutics's share price is $43.99. Sionna Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 was $6.39. Hence, Sionna Therapeutics's PB Ratio of today is 6.88.

The historical rank and industry rank for Sionna Therapeutics's PB Ratio or its related term are showing as below:

SION' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 6.88
Current: 6.88

During the past 4 years, Sionna Therapeutics's highest PB Ratio was 6.88. The lowest was 0.00. And the median was 0.00.

SION's PB Ratio is ranked worse than
78.01% of 1228 companies
in the Biotechnology industry
Industry Median: 2.97 vs SION: 6.88

Back to Basics: PB Ratio


Sionna Therapeutics  (NAS:SION) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Sionna Therapeutics PB Ratio Related Terms


Sionna Therapeutics PB Ratio Historical Data

* Premium members only.

The historical data trend for Sionna Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sionna Therapeutics PB Ratio Chart

Sionna Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
PB Ratio
0.00 0.00 0.00 6.00

Sionna Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 1.31 2.28 4.07 6.00 6.27

SION vs TYRA, RAPP, IOVA: PB Ratio Comparison

For the Biotechnology subindustry, Sionna Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sionna Therapeutics PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sionna Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Sionna Therapeutics's PB Ratio falls into.


SION
12GF Score
Sionna Therapeutics Inc SION
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sionna Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Sionna Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=43.99/6.394
=6.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Frequently Asked Questions Learn more about PB Ratio →
What does a PB Ratio of 6.88 mean?
Sionna Therapeutics (SION) has a PB Ratio of 6.88 as of Jul. 04, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sionna Therapeutics and its competitors. According to the industry distribution chart, Sionna Therapeutics ranks #958 out of 1228 companies in the Biotechnology industry, placing it in the top 78%.
Is Sionna Therapeutics' PB Ratio too high?
Sionna Therapeutics' current PB Ratio is 6.88. The Biotechnology industry median PB Ratio is 2.97. Sionna Therapeutics' value of 6.88 is 131.6% above this industry median. Based on the distribution chart, Sionna Therapeutics ranks #958 out of 1228 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sionna Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sionna Therapeutics' PB Ratio compare to TYRA and RAPP?
According to the Biotechnology industry distribution chart, Sionna Therapeutics ranks #958 out of 1228 companies for PB Ratio. This places Sionna Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.97. Sionna Therapeutics' value of 6.88 is 131.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.97, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sionna Therapeutics's current PB Ratio of 6.88 is 131.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sionna Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sionna Therapeutics's current PB Ratio is 6.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sionna Therapeutics stock overvalued right now?
Sionna Therapeutics (SION) has a current PB Ratio of 6.88. The current PB Ratio is 6.88 and 131.6% above the Biotechnology industry median of 2.97. Sionna Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Sionna Therapeutics (SION), the current PB Ratio is 6.88 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sionna Therapeutics Business Description

Address 21 Hickory Drive, Suite 500, Waltham, MA, USA, 02451
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
12GF Score

Get the complete analysis for SION

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$43.99
Price